Viral Pathogenesis and Host Damage

Viral pathogenesis is the process by which a virus produces disease in its host, spanning entry, spread, tissue damage, and resolution or persistence. It is distinct from viral replication mechanics — a virus can replicate perfectly and still cause no disease if it never reaches a vulnerable cell type or if the immune system controls it silently. The central determinant of where disease can even occur is tropism: the restriction of a given virus to particular species, tissues, or cell types. Tropism is set by at least three independent filters — availability of the specific receptor and coreceptor a virus needs for entry, the intracellular machinery (transcription factors, proteases, nucleotide pools) required for the virus to complete its replication cycle once inside, and physical or anatomical accessibility (mucus, pH, temperature, blood-tissue barriers). Once a susceptible cell is infected, the outcome falls along a spectrum. At one end is the cytopathic effect (CPE), direct cell damage or death caused by viral takeover of host machinery, immediately visible in cell culture as rounding, detachment, fusion into syncytia, or formation of inclusion bodies. At the other end is non-cytopathic persistence, where the virus coexists with a living cell for extended periods — sometimes for the life of the host — through latency, chronic low-level replication, or (rarely) slow infection with long incubation but eventual severe disease. A third possible outcome, transformation, occurs when instead of killing the cell or coexisting quietly, viral gene products push the cell into unregulated proliferation, a route to cancer exploited by several DNA and RNA tumor viruses. Layered over all of these is immune-mediated damage: because many symptoms of viral disease (fever, rash, tissue necrosis, organ failure) are produced not by the virus directly but by cytotoxic T lymphocytes, antibody-complement complexes, or inflammatory cytokines attacking infected or bystander cells.

Step 1 — Tropism is decided before a single viral gene is expressed. A virus must first physically reach a permissive cell. Poliovirus is ingested, survives stomach acid, and binds CD155 on gut epithelial and later motor neuron cells; it cannot infect cells lacking this receptor no matter how much virus is present. Rabies virus binds the nicotinic acetylcholine receptor at neuromuscular junctions and then travels retrograde along axons via dynein-mediated transport, explaining its slow, inexorable march from a bite wound toward the central nervous system. HIV requires both CD4 and a chemokine coreceptor (CCR5 or CXCR4), restricting its natural tropism to T helper cells, macrophages, and dendritic cells. Beyond receptor binding, post-entry restriction matters: influenza's polymerase requires specific host importins and ANP32 proteins that vary by species, which is why avian influenza strains often replicate poorly in human cells despite receptor binding, a bottleneck relevant to pandemic risk.

Step 2 — Cytopathic effect arises from specific molecular sabotage, not generic "damage." CPE is not a single phenomenon but the sum of several distinct molecular insults:

• Host shutoff: many viruses (poliovirus, herpes simplex virus) degrade host mRNA or inactivate translation initiation factors (cleaving eIF4G, for example) to redirect ribosomes toward viral transcripts, starving the cell of its own essential proteins.
• Membrane disruption: viroporins (influenza M2, poliovirus 2B) alter membrane permeability and ionic gradients; budding of enveloped viruses in large numbers physically damages the plasma membrane; lytic release of naked virions (poliovirus, adenovirus) ruptures the cell outright.
• Cell fusion: paramyxoviruses (measles, respiratory syncytial virus) express fusion (F) proteins on the cell surface that fuse infected cells with neighboring uninfected cells, forming multinucleated syncytia — the classic Warthin-Finkeldey giant cells seen in measles-infected lymph tissue.
• Cell-cycle arrest and apoptosis induction or suppression: many viruses initially block apoptosis (via Bcl-2 homologs or caspase inhibitors) to buy replication time, then trigger it late in infection to release progeny virions in membrane-bound apoptotic bodies that evade inflammation.
• Inclusion bodies: aggregates of viral proteins, nucleic acid, and assembly intermediates accumulate visibly — Negri bodies in rabies-infected neurons, Cowdry type A bodies in herpesvirus infection — useful as diagnostic markers precisely because they mark sites of intense viral factory activity.

Step 3 — Persistence requires evading or outlasting immune surveillance. Three distinct persistence strategies exist. Latency (herpesviruses) involves the viral genome circularizing as an episome in the nucleus (herpes simplex in sensory neurons, Epstein-Barr virus in memory B cells) with only a minimal set of latency-associated transcripts expressed, rendering infected cells nearly invisible to cytotoxic T cells that recognize processed viral peptides on MHC class I. Periodic reactivation, triggered by stress or immunosuppression, resumes full lytic replication. This is the eukaryotic viral parallel to the The Lysogenic Cycle in bacteriophages, though herpesviral latency uses episomal maintenance and epigenetic silencing rather than site-specific chromosomal integration as the default state. Chronic productive infection (hepatitis B and C, HIV) involves continuous low-to-moderate virus production that the immune system fails to clear completely, often because of rapid antigenic mutation (HIV's reverse transcriptase lacks proofreading, generating escape mutants faster than T cell responses can adapt) or active immune suppression (hepatitis B X protein interferes with interferon signaling). Slow infection describes agents with very long incubation periods before a single, severe, usually fatal disease episode — measles virus persisting in the brain for years before causing subacute sclerosing panencephalitis, or prions (not true viruses, but pathogenic proteins) causing spongiform encephalopathy after decades of silent accumulation.

Step 4 — Transformation redirects the cell cycle rather than destroying it. Oncogenic viruses fall into two mechanistic classes. Acute transforming retroviruses like Rous sarcoma virus carry a captured and mutated host proto-oncogene (v-src, a constitutively active tyrosine kinase) directly in their genome; a single infection event delivers an oncogene that drives uncontrolled proliferation. DNA tumor viruses (human papillomavirus, hepatitis B virus) instead encode regulatory proteins that inactivate host tumor suppressors: HPV E6 protein binds and targets p53 for degradation, while E7 binds and inactivates retinoblastoma protein (pRb), together releasing the brakes on cell-cycle progression at the G1/S checkpoint. Because these are normal viral genes hijacking normal cellular checkpoints rather than genes evolved "in order to" cause cancer, transformation is a byproduct of the virus's own strategy for keeping host cells alive and dividing long enough to support persistent low-level replication — cancer is an accidental side effect of that strategy, not its purpose. Insertional mutagenesis is a third, less common route: retroviral integration near a proto-oncogene can dysregulate its expression through the strong viral promoter, without the virus itself carrying an oncogene.

Step 5 — Much of what we call "viral disease" is actually immune-mediated damage. The adaptive immune system controls viral infection primarily through cytotoxic CD8+ T lymphocytes, which recognize viral peptides displayed on MHC class I and kill infected cells via perforin/granzyme-induced apoptosis or Fas-FasL signaling. This killing is necessary to clear infection but is not "gentle" — a T cell destroying every hepatocyte that expresses a hepatitis B peptide produces liver inflammation and damage that looks, clinically, exactly like viral hepatitis, even though the virus itself is not overtly cytopathic to hepatocytes. Antibody-mediated damage occurs through immune complex deposition (as in some cases of hepatitis B–associated glomerulonephritis) or complement-mediated lysis of infected cells. The most extreme form is the cytokine storm: excessive release of interleukin-6, tumor necrosis factor-alpha, and interferon-gamma by activated immune cells produces vascular leak, hypotension, and multi-organ failure disproportionate to the actual viral burden, a mechanism implicated in severe influenza, dengue hemorrhagic fever, and severe COVID-19.

Dulbecco's plaque assay (1952) — quantifying cytopathic effect. Renato Dulbecco developed a method to grow animal viruses in monolayers of cultured cells overlaid with a semisolid agar medium, directly adapting the bacteriophage plaque assay pioneered by Emory Ellis and Max Delbrück. Where a single infectious virus particle killed a cell, progeny virus could only spread to immediately adjacent cells (restricted by the agar overlay), producing a visible, countable clearing — a plaque — against the surrounding intact monolayer. This proved, quantitatively, that cytopathic effect follows a one-hit kinetic: plaque number is directly proportional to virus dilution, meaning a single virion is sufficient to initiate an infectious, lethal focus. It also gave virology its analogue of bacterial colony counting, the plaque-forming unit (PFU), still the standard unit of infectious titer today.

Peyton Rous and cell-free transmission of sarcoma (1911). Rous took a spontaneous connective-tissue tumor from a chicken, ground it up, passed the extract through a Chamberland filter fine enough to exclude bacteria and cells, and injected the cell-free filtrate into healthy chickens. Tumors developed at the injection site in the recipient birds. Because no cells or bacteria could have passed the filter, the transmissible agent had to be smaller than a cell — a virus (later named Rous sarcoma virus). This was the first direct demonstration that a virus could cause cancer, decades before oncogenes or reverse transcriptase were known; Rous received the Nobel Prize in Physiology or Medicine in 1966, remarkably 55 years after the original experiment, once the field had caught up enough to appreciate its significance.

Zinkernagel and Doherty — MHC restriction and immunopathology (1974). Rolf Zinkernagel and Peter Doherty studied mice infected with lymphocytic choriomeningitis virus (LCMV), a virus that is largely non-cytopathic to the neurons it infects in the meninges. They found that cytotoxic T lymphocytes from an infected mouse could kill LCMV-infected target cells in vitro only if the T cells and the target cells shared the same MHC class I haplotype — killing failed across MHC-mismatched combinations even when both were infected with identical virus. This established MHC restriction: T cells recognize viral antigen only in the context of self-MHC, the foundational principle of antigen presentation. Crucially, their broader body of work on LCMV also demonstrated that the severe meningitis seen in infected mice was not caused by the virus itself — mice with no functional T cells (immunodeficient or immunosuppressed) tolerated high viral loads in the brain with minimal disease, while immunocompetent mice mounting a vigorous CD8+ T cell response against infected meningeal cells developed fatal choriomeningitis. This was the founding demonstration that the immune response itself, not the virus, is the direct cause of disease in some infections — the two scientists shared the 1996 Nobel Prize.

Additional corroborating evidence. Epstein, Achong, and Barr's 1964 identification of Epstein-Barr virus particles by electron microscopy in Burkitt lymphoma cell lines, combined with later demonstration of EBV genome integration/episomal persistence in tumor cells, extended Rous's principle to a human herpesvirus and helped establish the multi-hit model of viral oncogenesis (viral gene action plus cofactors like malaria-driven immune dysregulation in endemic Burkitt lymphoma). Harald zur Hausen's identification of HPV DNA in cervical cancer biopsies in the 1980s, confirmed by demonstrating E6/E7 oncoprotein function in cell culture, earned the 2008 Nobel Prize and directly led to HPV vaccine development.

Example 1 — Reasoning through a clinical scenario: measles and immune suppression. A previously healthy 6-year-old develops the classic measles rash and fever, recovers within two weeks, but three months later dies of overwhelming bacterial pneumonia that would normally have been mild. Why? Measles virus infects not only respiratory epithelium (via the nectin-4 receptor, giving cough and coryza) but also lymphocytes and dendritic cells (via the SLAM/CD150 receptor), producing transient but profound depletion and functional impairment of memory B and T lymphocytes — a phenomenon called immune amnesia. The virus's tropism for immune cells (not just epithelium) is the mechanistic key: this is not simple immunosuppression from being sick, but active destruction and reprogramming of the memory lymphocyte repertoire that took years to build through prior infections and vaccinations. Epidemiological studies (Mina et al., 2015, using measurements of antibody repertoire breadth before and after natural measles infection in unvaccinated children) found immune amnesia persists for up to 2–3 years post-infection and quantitatively explains a measurable rise in all-cause childhood mortality from unrelated infections following measles outbreaks — a population-level signature of a cell-tropism effect invisible if you only looked at the measles rash itself.

Example 2 — A quantitative titer/pathogenesis calculation. A researcher inoculates two groups of mice intranasally with a recombinant respiratory virus: Group A receives 10² PFU, Group B receives 10⁶ PFU. Three days later, viral titers in lung homogenate and IL-6 concentrations in bronchoalveolar lavage fluid are measured:

Group B's lung titer is only 100-fold higher than Group A's, but its IL-6 is roughly 55-fold higher and mortality is substantial. If disease severity tracked linearly with viral load alone, Group B should be only modestly worse than Group A. The disproportionate rise in IL-6 relative to the modest rise in viral titer signals that innate immune activation and cytokine release, not viral replication per se, are driving pathology at high inoculum — consistent with cytokine-storm-type immunopathology. A rational follow-up experiment would treat a third cohort at the 10⁶ PFU dose with an IL-6 receptor blocker (as was actually done clinically with tocilizumab in severe COVID-19) and predict improved survival despite unchanged or even similar viral titers, since the intervention targets host response rather than the virus itself.

Peyton Rous trained as a pathologist at Johns Hopkins and joined the Rockefeller Institute for Medical Research in 1909, where a poultry farmer brought him a hen with a large breast tumor. Rather than simply describing the tumor histologically as was standard practice, Rous asked whether it could be transmitted — an unusual, almost heretical question for a solid tumor at the time, since cancer was widely assumed to be a purely cell-autonomous, non-infectious process. His cell-free filtrate experiments met with such skepticism from the medical establishment (many colleagues insisted his chicken tumors were flukes, or that avian cancer had nothing to teach about human disease) that he largely abandoned cancer virology for other research for almost two decades, returning to the field only as retroviruses and oncogenes became tractable to molecular study in the 1950s–60s. The 55-year gap between his discovery and his 1966 Nobel Prize remains one of the longest in the prize's history, a testament to how far ahead of available technique his original insight had been.

Understanding tropism drives vaccine and vector design: adeno-associated virus (AAV) gene therapy vectors are engineered with capsid variants selected for tropism toward liver, retina, or muscle, directly exploiting the receptor-based logic first worked out for natural viral pathogens. Understanding cytopathic mechanisms underlies antiviral drug design (foreshadowed in Antiviral Strategies and Drug Targets), where drugs targeting viral proteases or polymerases aim to blunt host-shutoff and lytic damage before it accumulates. Understanding persistence explains the clinical necessity of lifelong antiretroviral therapy in HIV (the latent reservoir in resting memory CD4 T cells is the central barrier to a cure) and the rationale for antiviral suppressive therapy in hepatitis B, where the goal is not eradication but preventing the immune-mediated liver damage that chronic infection provokes. Understanding transformation underlies two of the most successful cancer-prevention tools in modern medicine: the HPV vaccine, which has produced measurable declines in cervical cancer incidence in vaccinated cohorts, and the hepatitis B vaccine, credited with reducing hepatocellular carcinoma rates in previously high-incidence regions like Taiwan. Finally, understanding immunopathology has reshaped critical care during the COVID-19 pandemic, where corticosteroids (dexamethasone) and IL-6 pathway blockers became standard therapy for severe disease specifically because much of the late-stage lung damage is immune-driven rather than directly viral — the clinical embodiment of the Zinkernagel–Doherty principle, and a pattern virologists now watch for in every newly emerging pandemic pathogen.

Ask the tutor: How does antigenic variation in a persistent virus like HIV interact with MHC restriction to allow long-term immune escape?